Inducer | Dose Regimen | Cmax, ss | Reference |
---|---|---|---|
μM | |||
BST | 125 mg b.i.d. 5 days | 2.0 | Dingemanse et al., 2003 |
BST | 500 mg b.i.d. 7 days | 14.4 | Binet et al., 2000 |
DEX | 8 mg, b.i.d., 5 days | 0.1 | McCune et al., 2000 |
CMZ | 50 mg b.i.d. 2 wk | 8.0 | Yasui-Furukori et al., 2003 |
CMZ | 100 mg t.i.d. 10 days | 17.8 | Furukori et al., 1998 |
CMZ | 150 mg b.i.d. 2 wk | 17.7 | Yasui-Furukori et al., 2003 |
CMZ | 200 mg b.i.d. 4 days or q.d. 5 days | 13.5-22.8 | Otani et al., 1996a; Masui et al., 2006 |
CMZ | 300 mg b.i.d. 2 wk | 25.0 | Yasui-Furukori et al., 2003 |
CMZ | 400 mg q.d. 4 wk | 20.3-23.3 | Otani et al., 1996b; Schlienger et al., 2000 |
CMZ | 600 mg q.d. 9 wk | 22.0-33.0 | de Leon and Bork, 1997; Licht et al., 2000 |
CMZ | 800 mg q.d. 7 days | 31.3 | Hillebrand et al., 1987 |
CMZ | 942 mg 6 wk | 39.8 | Ketter et al., 1995 |
CMZ | 1400-1650 mg (chronic) | 40.8-41.7 | May et al., 1996, 2003 |
EFA | 200 or 400 mg q.d. 10 days | 6.9 | Mouly et al., 2002 |
EFA | 600 mg q.d. 10 days | 10.6-14.9 | Veldkamp et al., 2001; la Porte et al., 2004b; Weiner et al., 2005 |
EFA | 800 mg q.d. 7 days | 11.31 | Lopez-Cortes et al., 2002 |
PB | 30 mg b.i.d. (chronic) | 31.2-36.6 | Back et al., 1980 |
PB | 90 mg q.d. 29 days | 56.8-66.3 | Ferron et al., 2003 |
PB | 100 mg q.d. 21 days | 59.0-65.0 | Kapil et al., 1987; Rutledge et al., 1988 |
PB | 140 mg q.d. 19 days | 123.6 | Saccar et al., 1985 |
PB | 200 mg q.d. 7 days | 105.0 | Williams et al., 1983 |
RIF | 300 mg b.i.d. 13.5 days | 4.1-8.9 | Drusano et al., 1986;Chandler et al., 1990 |
RIF | 600 mg q.d. 10 days | 10.2-18.2 | Boyd et al., 2003b; la Porte et al., 2004a; Stone et al., 2004; Droste et al., 2005 |
RIF | 900 mg q.d. 10 days | 12.1 | Humbert et al., 1991 |